In this OncLive® My Treatment Approach program, Wade Iams, MD, MSCI, is joined by Matthew Gumbleton, MD, PhD, and Estelamari Rodriguez, MD, MPH, for an in-depth discussion on navigating the evolving first-line treatment landscape in EGFR-mutant metastatic non–small cell lung cancer. The panel reviews key evidence from pivotal phase III trials, including MARIPOSA and FLAURA2, comparing combination strategies such as amivantamab plus lazertinib and chemotherapy plus osimertinib against osimertinib monotherapy. Topics include CNS disease management, TP53 co-mutation as a high-risk feature, and practical strategies for managing dermatologic toxicity, VTE prophylaxis, and dose modifications. Two illustrative patient cases anchor the discussion, highlighting how disease burden, molecular profile, patient priorities, and logistical considerations together shape individualized treatment decisions in clinical practice.
This segment frames the current first-line treatment landscape for EGFR-mutant metastatic non–small cell lung cancer and how it has evolved over two decades.
This episode explores how overall survival data, toxicity profiles, and guideline categorizations inform frontline decision-making.
Experts weigh NCCN category 1 value and show how serial brain MRIs shape EGFR lung cancer first-line treatment decisions.
Experts compare EGFR lung cancer first-line combos, weighing chemo vs amivantamab-lazurtnib toxicity, quality of life, and patient-centered choice.
Experts weigh combo therapy for EGFR L858R/TP53 lung cancer with brain mets, balancing radiation and systemic options to cut visits.
Experts weigh EGFR L858R/TP53 stage IV NSCLC options, combo regimens and brain-met strategies to boost control, ease visits.
Learn practical systems for managing EGFR therapy side effects, triage tips, and what’s next for resistance in metastatic NSCLC.
